{"id":2535,"date":"2018-02-06T22:04:22","date_gmt":"2018-02-06T16:34:22","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=2535"},"modified":"2021-07-24T12:56:56","modified_gmt":"2021-07-24T07:26:56","slug":"notizia-latest-pharma-news","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/notizia-latest-pharma-news","title":{"rendered":"Notizia"},"content":{"rendered":"<p style=\"text-align: justify;\"><strong>Charles River to fuel hit discovery with AstraZeneca high-throughput collaboration<\/strong><\/p>\n<p style=\"text-align: justify;\">After collaborating with AstraZeneca Charles River is now looking forward to strengthening its high-throughput screening capabilities (HTC) with the help of highly advance AstraZeneca technology. Now the company is able to offer the clients access to a screening facility with highly high-resolution, flexible, automated screening platforms. The collaboration has also enabled Charles River Laboratories to offer state-of-the-art assay detection platforms for label-free and imaging-based assays, along with the ability to run novel technologies, including acoustic mass spectrometry.<\/p>\n<p style=\"text-align: justify;\"><strong>JDRF and Cam Med have joined forces on insulin patch pump for artificial pancreas<\/strong><\/p>\n<p style=\"text-align: justify;\">JDRF and Cam Med have joined forces to develop a bandage-like insulin patch pump for next-generation \u201cartificial pancreas\u201d systems. JDRF has funded Cam Med, a biotech company specialized in microfluidic-based drug delivery. The company will now advance its Evopump, a thin and flexible pump designed for the delivery of one or more medications.<\/p>\n<p style=\"text-align: justify;\"><strong>After FDA setback, Bellicum Pharma is all geared up with new R&amp;D leadership, an ex-Genentech executive<\/strong><\/p>\n<p style=\"text-align: justify;\">Bellicum Pharma is all geared up just a few days after the FDA placed a clinical hold on its lead cell therapy for cancer, Pharma company has recently added new R&amp;D leadership by appointing ex-Genentech executive William Grossman as its chief medical officer. The company is looking forward to improving the R&amp;D process under new supervision.<\/p>\n<p style=\"text-align: justify;\"><strong>British biotech ReViral successfully achieved primary and secondary endpoints in early RSV test<\/strong><\/p>\n<p style=\"text-align: justify;\">Biotechnology Company ReViral has successfully met its primary and secondary endpoints in a small midstage clinical trial for its experimental med against the respiratory syncytial virus (RSV). The phase II a placebo-controlled test of its oral\u00a0<strong>RSV fusion inhibitor RV521<\/strong>, given to adults infected with the virus, significantly reduced viral load, reduced total mucus weight and reduced clinical symptoms, compared to a control treatment with no safety concerns as per the reports.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Charles River to fuel hit discovery with AstraZeneca high-throughput collaboration After collaborating with AstraZeneca Charles River is now looking forward to strengthening its high-throughput screening capabilities (HTC) with the help of highly advance AstraZeneca technology. Now the company is able to offer the clients access to a screening facility with highly high-resolution, flexible, automated screening [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":2465,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[32],"tags":[1361,1364,96,1365,1363,1307,204,1366,704,1359,1360,1362,349,1230,1182,639,17615,1368,2010,1369,1367],"industry":[17225],"therapeutic_areas":[17240,17231],"class_list":["post-2535","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizia","tag-acoustic-mass-spectrometry","tag-artificial-pancreas","tag-astrazeneca","tag-bellicum-pharma","tag-cam-med","tag-charles-river","tag-delveinsight","tag-ex-genentech-executive","tag-fda","tag-high-throughput-screening-capabilities","tag-htc","tag-jdrf","tag-latest-pharma-news","tag-pharma-consultancy","tag-pharma-consultants","tag-pharma-news","tag-respiratory-syncytial-virus","tag-reviral","tag-rsv","tag-rsv-test","tag-william-grossman","industry-pharmaceutical","therapeutic_areas-endocrinology-and-metabolic-disorders","therapeutic_areas-infectious-diseases"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Notizia-Delveinsight&#039;s latest pharma news updates<\/title>\n<meta name=\"description\" content=\"After collaborating with AstraZeneca Charles River is now looking forward to strengthening its high-throughput screening capabilities (HTC)\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/notizia-latest-pharma-news\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Notizia-Delveinsight&#039;s latest pharma news updates\" \/>\n<meta property=\"og:description\" content=\"After collaborating with AstraZeneca Charles River is now looking forward to strengthening its high-throughput screening capabilities (HTC)\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/notizia-latest-pharma-news\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2018-02-06T16:34:22+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2021-07-24T07:26:56+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2017\/12\/09021225\/Notizia.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1112\" \/>\n\t<meta property=\"og:image:height\" content=\"660\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Notizia-Delveinsight's latest pharma news updates","description":"After collaborating with AstraZeneca Charles River is now looking forward to strengthening its high-throughput screening capabilities (HTC)","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/notizia-latest-pharma-news","og_locale":"en_US","og_type":"article","og_title":"Notizia-Delveinsight's latest pharma news updates","og_description":"After collaborating with AstraZeneca Charles River is now looking forward to strengthening its high-throughput screening capabilities (HTC)","og_url":"https:\/\/www.delveinsight.com\/blog\/notizia-latest-pharma-news","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2018-02-06T16:34:22+00:00","article_modified_time":"2021-07-24T07:26:56+00:00","og_image":[{"width":1112,"height":660,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2017\/12\/09021225\/Notizia.png","type":"image\/png"}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/notizia-latest-pharma-news","url":"https:\/\/www.delveinsight.com\/blog\/notizia-latest-pharma-news","name":"Notizia-Delveinsight's latest pharma news updates","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/notizia-latest-pharma-news#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/notizia-latest-pharma-news#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2017\/12\/09021225\/Notizia.png","datePublished":"2018-02-06T16:34:22+00:00","dateModified":"2021-07-24T07:26:56+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a"},"description":"After collaborating with AstraZeneca Charles River is now looking forward to strengthening its high-throughput screening capabilities (HTC)","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/notizia-latest-pharma-news"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/notizia-latest-pharma-news#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2017\/12\/09021225\/Notizia.png","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2017\/12\/09021225\/Notizia.png","width":1112,"height":660,"caption":"transthyretin amyloidosis"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/gtadmin"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2017\/12\/09021225\/Notizia-300x178.png","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">acoustic mass spectrometry<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">artificial pancreas<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">AstraZeneca<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Bellicum Pharma<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Cam Med<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Charles River<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">DelveInsight<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">ex-Genentech executive<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">FDA<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">high-throughput screening capabilities<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">HTC<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">JDRF<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Latest pharma news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">pharma consultancy<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">pharma consultants<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">pharma news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Respiratory Syncytial Virus<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">ReViral<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">RSV<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">RSV test<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">William Grossman<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">acoustic mass spectrometry<\/span>","<span class=\"advgb-post-tax-term\">artificial pancreas<\/span>","<span class=\"advgb-post-tax-term\">AstraZeneca<\/span>","<span class=\"advgb-post-tax-term\">Bellicum Pharma<\/span>","<span class=\"advgb-post-tax-term\">Cam Med<\/span>","<span class=\"advgb-post-tax-term\">Charles River<\/span>","<span class=\"advgb-post-tax-term\">DelveInsight<\/span>","<span class=\"advgb-post-tax-term\">ex-Genentech executive<\/span>","<span class=\"advgb-post-tax-term\">FDA<\/span>","<span class=\"advgb-post-tax-term\">high-throughput screening capabilities<\/span>","<span class=\"advgb-post-tax-term\">HTC<\/span>","<span class=\"advgb-post-tax-term\">JDRF<\/span>","<span class=\"advgb-post-tax-term\">Latest pharma news<\/span>","<span class=\"advgb-post-tax-term\">pharma consultancy<\/span>","<span class=\"advgb-post-tax-term\">pharma consultants<\/span>","<span class=\"advgb-post-tax-term\">pharma news<\/span>","<span class=\"advgb-post-tax-term\">Respiratory Syncytial Virus<\/span>","<span class=\"advgb-post-tax-term\">ReViral<\/span>","<span class=\"advgb-post-tax-term\">RSV<\/span>","<span class=\"advgb-post-tax-term\">RSV test<\/span>","<span class=\"advgb-post-tax-term\">William Grossman<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 8 years ago","modified":"Updated 5 years ago"},"absolute_dates":{"created":"Posted on Feb 6, 2018","modified":"Updated on Jul 24, 2021"},"absolute_dates_time":{"created":"Posted on Feb 6, 2018 10:04 pm","modified":"Updated on Jul 24, 2021 12:56 pm"},"featured_img_caption":"transthyretin amyloidosis","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/2535","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=2535"}],"version-history":[{"count":0,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/2535\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/2465"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=2535"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=2535"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=2535"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=2535"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=2535"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}